Chronic Activation of Innate Immunity Correlates With Poor Prognosis in Cancer Patients Treated With Oncolytic Adenovirus

Kristian Taipale; Ilkka Liikanen; Juuso Juhila; Riku Turkki; Siri Tahtinen; Matti Kankainen; Lotta Vassilev; Ari Ristimaki; Anniina Koski; Anna Kanerva; Iulia Diaconu; Vincenzo Cerullo; Markus Vaha-Koskela; Minna Oksanen; Nina Linder; Timo Joensuu; Johan Lundin; Akseli Hemminki

doi:10.1038/mt.2015.143

Chronic Activation of Innate Immunity Correlates With Poor Prognosis in Cancer Patients Treated With Oncolytic Adenovirus

Kristian Taipale, Ilkka Liikanen, Juuso Juhila, Riku Turkki, Siri Tahtinen, Matti Kankainen, Lotta Vassilev, Ari Ristimaki, Anniina Koski, Anna Kanerva, Iulia Diaconu, Vincenzo Cerullo, Markus Vaha-Koskela, Minna Oksanen, Nina Linder, Timo Joensuu, Johan Lundin, Akseli Hemminki

Research output: Contribution to journal › Article › Scientific › peer-review

Original language	English
Journal	Molecular therapy
Volume	24
Issue number	1
Pages (from-to)	175-183
Number of pages	9
ISSN	1525-0016
DOIs	https://doi.org/10.1038/mt.2015.143
Publication status	Published - Jan 2016
MoE publication type	A1 Journal article-refereed

Fields of Science

REFRACTORY SOLID TUMORS
T-CELL EXHAUSTION
B-CELLS
IMMUNOTHERAPY
CHEMOTHERAPY
INTERFERON
BLOCKADE
SURVIVAL
MACROPHAGES
VIROTHERAPY
3111 Biomedicine

Access to Document

10.1038/mt.2015.143

Cite this

Taipale, K., Liikanen, I., Juhila, J., Turkki, R., Tahtinen, S., Kankainen, M., Vassilev, L., Ristimaki, A., Koski, A., Kanerva, A., Diaconu, I., Cerullo, V., Vaha-Koskela, M., Oksanen, M., Linder, N., Joensuu, T., Lundin, J., & Hemminki, A. (2016). Chronic Activation of Innate Immunity Correlates With Poor Prognosis in Cancer Patients Treated With Oncolytic Adenovirus. Molecular therapy, 24(1), 175-183. https://doi.org/10.1038/mt.2015.143

@article{b7a2cc8d6ec740dc8bea1141c3707659,

title = "Chronic Activation of Innate Immunity Correlates With Poor Prognosis in Cancer Patients Treated With Oncolytic Adenovirus",

keywords = "REFRACTORY SOLID TUMORS, T-CELL EXHAUSTION, B-CELLS, IMMUNOTHERAPY, CHEMOTHERAPY, INTERFERON, BLOCKADE, SURVIVAL, MACROPHAGES, VIROTHERAPY, 3111 Biomedicine",

author = "Kristian Taipale and Ilkka Liikanen and Juuso Juhila and Riku Turkki and Siri Tahtinen and Matti Kankainen and Lotta Vassilev and Ari Ristimaki and Anniina Koski and Anna Kanerva and Iulia Diaconu and Vincenzo Cerullo and Markus Vaha-Koskela and Minna Oksanen and Nina Linder and Timo Joensuu and Johan Lundin and Akseli Hemminki",

year = "2016",

month = jan,

doi = "10.1038/mt.2015.143",

language = "English",

volume = "24",

pages = "175--183",

journal = "Molecular therapy",

issn = "1525-0016",

publisher = "Cell Press",

number = "1",

}

Taipale, K, Liikanen, I, Juhila, J, Turkki, R, Tahtinen, S, Kankainen, M, Vassilev, L, Ristimaki, A , Koski, A , Kanerva, A, Diaconu, I, Cerullo, V , Vaha-Koskela, M , Oksanen, M , Linder, N, Joensuu, T, Lundin, J & Hemminki, A 2016, 'Chronic Activation of Innate Immunity Correlates With Poor Prognosis in Cancer Patients Treated With Oncolytic Adenovirus', Molecular therapy, vol. 24, no. 1, pp. 175-183. https://doi.org/10.1038/mt.2015.143

TY - JOUR

T1 - Chronic Activation of Innate Immunity Correlates With Poor Prognosis in Cancer Patients Treated With Oncolytic Adenovirus

AU - Taipale, Kristian

AU - Liikanen, Ilkka

AU - Juhila, Juuso

AU - Turkki, Riku

AU - Tahtinen, Siri

AU - Kankainen, Matti

AU - Vassilev, Lotta

AU - Ristimaki, Ari

AU - Koski, Anniina

AU - Kanerva, Anna

AU - Diaconu, Iulia

AU - Cerullo, Vincenzo

AU - Vaha-Koskela, Markus

AU - Oksanen, Minna

AU - Linder, Nina

AU - Joensuu, Timo

AU - Lundin, Johan

AU - Hemminki, Akseli

PY - 2016/1

Y1 - 2016/1

KW - REFRACTORY SOLID TUMORS

KW - T-CELL EXHAUSTION

KW - B-CELLS

KW - IMMUNOTHERAPY

KW - CHEMOTHERAPY

KW - INTERFERON

KW - BLOCKADE

KW - SURVIVAL

KW - MACROPHAGES

KW - VIROTHERAPY

KW - 3111 Biomedicine

U2 - 10.1038/mt.2015.143

DO - 10.1038/mt.2015.143

M3 - Article

SN - 1525-0016

VL - 24

SP - 175

EP - 183

JO - Molecular therapy

JF - Molecular therapy

IS - 1

ER -